| CORP. ACQUISITION |
PPL unit sold to group led by medical center Regenecor Holdings, a group of investors led by the University of Pittsburgh Medical Center, has acquired PPL Therapeutics Inc., a Virginia-based subsidiary of Scotland's PPL Therapeutics Plc, for $3.5 million. The parent company, which focuses on the production of human proteins in transgenic animals, will transfer its regenerative medicine assets to Regenecor in return for a 22.2% interest in the new company. The business includes R&D programs in xenotransplantation, stem cell technologies for treating diabetes and neurological diseases, and infectious disease technologies based on polyclonal antibodies in genetically modified livestock. The center says its investment is "taking to the next level" a scientific collaboration between its Thomas E. Starzl Transplantation Institute and PPL. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |